The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Subjects
4.2. Clinical and Neuropsychological Assessments
4.3. PET Imaging
4.4. Statistical Analysis
Author Contributions
Funding
Conflicts of Interest
References
- Halliday, G.; Hely, M.; Reid, W.; Morris, J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol. 2008, 115, 409–415. [Google Scholar] [CrossRef] [PubMed]
- Hely, M.A.; Reid, W.G.; Adena, M.A.; Halliday, G.M.; Morris, J.G. The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov. Disord. 2008, 23, 837–844. [Google Scholar] [CrossRef] [PubMed]
- Adler, C.H.; Caviness, J.N.; Sabbagh, M.N.; Shill, H.A.; Connor, D.J.; Sue, L.; Evidente, V.G.; Driver-Dunckley, E.; Beach, T.G. Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol. 2010, 120, 827–828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jellinger, K.; Seppi, K.; Wenning, G.; Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J. Neural Transm. 2002, 109, 329–339. [Google Scholar] [CrossRef] [PubMed]
- Papapetropoulos, S.; Lieberman, A.; Gonzalez, J.; Mash, D.C. Can Alzheimer’s type pathology influence the clinical phenotype of Parkinson’s disease? Acta Neurol. Scand. 2005, 111, 353–359. [Google Scholar] [CrossRef]
- Irwin, D.J.; Lee, V.M.-Y.; Trojanowski, J.Q. Parkinson’s disease dementia: Convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 2013, 14, 626. [Google Scholar] [CrossRef]
- Morris, E.; Chalkidou, A.; Hammers, A.; Peacock, J.; Summers, J.; Keevil, S. Diagnostic accuracy of 18 F amyloid PET tracers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 374–385. [Google Scholar] [CrossRef] [Green Version]
- Gomperts, S.N.; Locascio, J.J.; Rentz, D.; Santarlasci, A.; Marquie, M.; Johnson, K.A.; Growdon, J.H. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013, 80, 85–91. [Google Scholar] [CrossRef] [Green Version]
- Edison, P.; Rowe, C.C.; Rinne, J.O.; Ng, S.; Ahmed, I.; Kemppainen, N.; Villemagne, V.L.; O’Keefe, G.; Någren, K.; Chaudhury, K. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 2008, 79, 1331–1338. [Google Scholar] [CrossRef]
- Maetzler, W.; Liepelt, I.; Reimold, M.; Reischl, G.; Solbach, C.; Becker, C.; Schulte, C.; Leyhe, T.; Keller, S.; Melms, A. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis. 2009, 34, 107–112. [Google Scholar] [CrossRef]
- Maetzler, W.; Reimold, M.; Liepelt, I.; Solbach, C.; Leyhe, T.; Schweitzer, K.; Eschweiler, G.W.; Mittelbronn, M.; Gaenslen, A.; Uebele, M. [11C] PIB binding in Parkinson’s disease dementia. Neuroimage 2008, 39, 1027–1033. [Google Scholar] [CrossRef] [PubMed]
- Gomperts, S.; Rentz, D.; Moran, E.; Becker, J.; Locascio, J.; Klunk, W.; Mathis, C.; Elmaleh, D.; Shoup, T.; Fischman, A. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71, 903–910. [Google Scholar] [CrossRef] [PubMed]
- Petrou, M.; Bohnen, N.I.; Müller, M.L.; Koeppe, R.A.; Albin, R.L.; Frey, K.A. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012, 79, 1161–1167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akhtar, R.S.; Xie, S.X.; Brennan, L.; Pontecorvo, M.J.; Hurtig, H.I.; Trojanowski, J.Q.; Weintraub, D.; Siderowf, A.D. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer’s Pathology in Parkinson’s Disease Dementia. Mov. Disord. Clin. Pract. 2016, 3, 367–375. [Google Scholar] [CrossRef]
- Galvin, J.E.; Pollack, J.; Morris, J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006, 67, 1605–1611. [Google Scholar] [CrossRef]
- Mastaglia, F.L.; Johnsen, R.D.; Byrnes, M.L.; Kakulas, B.A. Prevalence of amyloid-β deposition in the cerebral cortex in Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2003, 18, 81–86. [Google Scholar] [CrossRef]
- Sabbagh, M.N.; Adler, C.H.; Lahti, T.J.; Connor, D.J.; Vedders, L.; Peterson, L.K.; Caviness, J.N.; Shill, H.A.; Sue, L.I.; Ziabreva, I. Parkinson’s disease with dementia: Comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 2009, 23, 295. [Google Scholar] [CrossRef]
- Lashley, T.; Holton, J.L.; Gray, E.; Kirkham, K.; O’Sullivan, S.S.; Hilbig, A.; Wood, N.W.; Lees, A.J.; Revesz, T. Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol. 2008, 115, 417–425. [Google Scholar] [CrossRef]
- Pletnikova, O.; West, N.; Lee, M.K.; Rudow, G.L.; Skolasky, R.L.; Dawson, T.M.; Marsh, L.; Troncoso, J.C. Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases. Neurobiol. Aging 2005, 26, 1183–1192. [Google Scholar] [CrossRef]
- Mikolaenko, I.; Pletnikova, O.; Kawas, C.H.; O’brien, R.; Resnick, S.M.; Crain, B.; Troncoso, J.C. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 2005, 64, 156–162. [Google Scholar] [CrossRef]
- Masliah, E.; Rockenstein, E.; Veinbergs, I.; Sagara, Y.; Mallory, M.; Hashimoto, M.; Mucke, L. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2001, 98, 12245–12250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Emre, M.; Aarsland, D.; Brown, R.; Burn, D.J.; Duyckaerts, C.; Mizuno, Y.; Broe, G.A.; Cummings, J.; Dickson, D.W.; Gauthier, S. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2007, 22, 1689–1707. [Google Scholar] [CrossRef] [PubMed]
- Kehagia, A.A.; Barker, R.A.; Robbins, T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010, 9, 1200–1213. [Google Scholar] [CrossRef]
- Clark, C.M.; Pontecorvo, M.J.; Beach, T.G.; Bedell, B.J.; Coleman, R.E.; Doraiswamy, P.M.; Fleisher, A.S.; Reiman, E.M.; Sabbagh, M.N.; Sadowsky, C.H. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol. 2012, 11, 669–678. [Google Scholar] [CrossRef]
- Melzer, T.R.; Stark, M.R.; Keenan, R.J.; Myall, D.J.; MacAskill, M.R.; Pitcher, T.L.; Livingston, L.; Grenfell, S.; Horne, K.L.; Young, B.N.; et al. Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson’s Disease. Front. Neurol. 2019, 10, 391. [Google Scholar] [CrossRef]
- Antonelli, F.; Ray, N.; Strafella, A.P. Imaging cognitive and behavioral symptoms in Parkinson’s disease. Expert Rev. Neurother. 2010, 10, 1827–1838. [Google Scholar] [CrossRef]
- Compta, Y.; Parkkinen, L.; O’sullivan, S.S.; Vandrovcova, J.; Holton, J.L.; Collins, C.; Lashley, T.; Kallis, C.; Williams, D.R.; de Silva, R. Lewy-and Alzheimer-type pathologies in Parkinson’s disease dementia: Which is more important? Brain 2011, 134, 1493–1505. [Google Scholar] [CrossRef] [Green Version]
- Compta, Y.; Parkkinen, L.; Kempster, P.; Selikhova, M.; Lashley, T.; Holton, J.L.; Lees, A.J.; Revesz, T. The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson’s disease progression and related dementia. Neurodegener. Dis. 2014, 13, 154–156. [Google Scholar] [CrossRef]
- Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55, 181–184. [Google Scholar] [CrossRef] [Green Version]
- Tomlinson, C.L.; Stowe, R.; Patel, S.; Rick, C.; Gray, R.; Clarke, C.E. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 2010, 25, 2649–2653. [Google Scholar] [CrossRef]
- Kang, Y.; Na, D.; Hahn, S. Seoul Neuropsychological Screening Battery; Human Brain Research & Consulting Co.: Seoul, Korea, 2003. [Google Scholar]
- Sabri, O.; Sabbagh, M.N.; Seibyl, J.; Barthel, H.; Akatsu, H.; Ouchi, Y.; Senda, K.; Murayama, S.; Ishii, K.; Takao, M. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study. Alzheimer’s Dement. 2015, 11, 964–974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Aβ− | Aβ+ | ||
---|---|---|---|
n = 19 | n = 4 | p Value | |
Age | 73.4 ± 6.0 | 74.8 ± 4.6 | 0.8574 |
Female | 5 (26.3%) | 2 (50.0%) | 0.5573 |
H&Y stage | 2.3 ± 1.1 | 1.6 ± 0.5 | 0.3164 |
UPDRS part III | 16.6 ± 9.2 | 11.8 ± 5.7 | 0.2422 |
LEDD (mg) | 786 ± 338 | 600 ± 491 | 0.5128 |
Educational level (years) | 8.3 ± 5.3 | 8.5 ± 2.6 | 0.9904 |
MMSE | 23.1 ± 4.5 | 21.0 ± 6.4 | 0.4069 |
CDR | 0.6 ± 0.2 | 0.9 ± 0.8 | 0.6717 |
CDR-SB | 2.2 ± 2.1 | 4.1 ± 4.7 | 0.4305 |
GDS-SF | 5.2 ± 3.6 | 8.0 ± 7.0 | 0.5407 |
NPI | 7.2 ± 13.0 | 32.0 ± 37.0 | 0.0366 |
Aβ− | Aβ+ | ||
---|---|---|---|
n = 19 | n = 4 | p Value | |
Digit span forward | 5.9 ± 1.6 | 6.5 ± 2.1 | 0.528 |
Digit span backward | 2.7 ± 1.5 | 2.8 ± 0.5 | 0.713 |
COWAT-animal | 10.2 ± 3.5 | 6.5 ± 3.8 | 0.095 |
COWAT-phonemic | 13.0 ± 8.0 | 3.0 ± 2.4 | 0.013 |
Stroop test | 48.5 ± 27.5 | 41.7 ± 22.2 | 0.748 |
Rey complex figure copy | 25.4 ± 10.0 | 21.4 ± 14.4 | 0.442 |
Boston naming test | 35.5 ± 12.8 | 27.5 ± 9.1 | 0.171 |
SVLT delayed recall | 2.7 ± 2.4 | 0.5 ± 0.6 | 0.114 |
RCFT delayed recall | 5.6 ± 6.5 | 1.6 ± 3.2 | 0.327 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Na, S.; Jeong, H.; Park, J.-S.; Chung, Y.-A.; Song, I.-U. The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia. Metabolites 2020, 10, 380. https://doi.org/10.3390/metabo10100380
Na S, Jeong H, Park J-S, Chung Y-A, Song I-U. The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia. Metabolites. 2020; 10(10):380. https://doi.org/10.3390/metabo10100380
Chicago/Turabian StyleNa, Seunghee, Hyeonseok Jeong, Jong-Sik Park, Yong-An Chung, and In-Uk Song. 2020. "The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia" Metabolites 10, no. 10: 380. https://doi.org/10.3390/metabo10100380